UBS Group’s Enliven Therapeutics ELVN Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Shares Change % | Capital Flow | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q2 | $2.77M | Buy |
138,280
+67,844
| +96% | +$1.36M | ﹤0.01% | 3553 |
|
|
2025
Q1 | $1.39M | Sell |
70,436
-16,752
| -19% | -$330K | ﹤0.01% | 3956 |
|
|
2024
Q4 | $1.96M | Buy |
87,188
+59,506
| +215% | +$1.34M | ﹤0.01% | 3727 |
|
|
2024
Q3 | $707K | Buy |
27,682
+7,564
| +38% | +$193K | ﹤0.01% | 3857 |
|
|
2024
Q2 | $470K | Sell |
20,118
-6,717
| -25% | -$157K | ﹤0.01% | 3966 |
|
|
2024
Q1 | $472K | Buy |
+26,835
| New | +$472K | ﹤0.01% | 4145 |
|
|
2023
Q4 | – | Sell |
-105
| Closed | -$1.43K | – | 8191 |
|
|
2023
Q3 | $1.43K | Buy |
105
+24
| +30% | +$328 | ﹤0.01% | 6796 |
|
|
2023
Q2 | $1.65K | Sell |
81
-253
| -76% | -$5.16K | ﹤0.01% | 6796 |
|
|
2023
Q1 | $7.32K | Sell |
334
-377
| -53% | -$8.26K | ﹤0.01% | 6720 |
|
|
2022
Q4 | $11.6K | Buy |
+711
| New | +$11.6K | ﹤0.01% | 7182 |
|
|
2022
Q1 | – | Sell |
-1,121
| Closed | -$10K | – | 9269 |
|
|
2021
Q4 | $10K | Buy |
+1,121
| New | +$10K | ﹤0.01% | 7648 |
|
|
2021
Q3 | – | Sell |
-536
| Closed | -$17K | – | 8455 |
|
|
2021
Q2 | $17K | Buy |
536
+126
| +31% | +$4K | ﹤0.01% | 6409 |
|
|
2021
Q1 | $14K | Buy |
410
+131
| +47% | +$4.47K | ﹤0.01% | 6646 |
|
|
2020
Q4 | $25K | Buy |
+279
| New | +$25K | ﹤0.01% | 5766 |
|
|
2020
Q3 | – | Sell |
-391
| Closed | -$43K | – | 7147 |
|
|
2020
Q2 | $43K | Buy |
+391
| New | +$43K | ﹤0.01% | 5140 |
|